Clinical Trials on Irritable Bowel in South Africa

Total 363 results

University of Stellenbosch
Nestlè Nutrition Institute Africa; National Research Foundation (NRF) (RSA)

Completed

Effect of Lactobacillus Plantarum 299v on Symptoms of Irritable Bowel Syndrome

Irritable Bowel Syndrome

South Africa
GlaxoSmithKline

Completed

A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)

Irritable Bowel Syndrome (IBS)

Germany, Australia, France
GlaxoSmithKline

Completed

Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome

Irritable Bowel Syndrome (IBS)

United States, Canada
GlaxoSmithKline

Completed

A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers

Irritable Bowel Syndrome

Australia
GlaxoSmithKline

Completed

A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers

Irritable Bowel Syndrome

Australia
GlaxoSmithKline

Completed

A Phase I, Randomized, Placebo-controlled, Double Blind, Repeat Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106 in Normal Subjects

Irritable Bowel Syndrome

Australia
Ardelyx

Enrolling by invitation

Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C

Irritable Bowel Syndrome With Constipation (IBS-C)

United States
Rutgers, The State University of New Jersey
Harokopio University

Completed

A Study of Chios Mastic Water in Irritable Bowel Syndrome (MASTIQUA)

Irritable Bowel Syndrome

Greece
GlaxoSmithKline

Completed

Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy

Irritable Bowel Syndrome (IBS) | Irritable Colon

United States, Australia
Ardelyx

Recruiting

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

Irritable Bowel Syndrome With Constipation (IBS-C)

United States
GlaxoSmithKline

Completed

Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy

Irritable Bowel Syndrome (IBS) | Irritable Colon

United States, Australia
Ono Pharma USA Inc

Completed

A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) (RESTORE)

Irritable Bowel Syndrome (IBS)

United States
Ardelyx

Completed

A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)

Constipation Predominant Irritable Bowel Syndrome

United States
Ardelyx

Completed

A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C (T3MPO-1)

Constipation Predominant Irritable Bowel Syndrome

United States
GlaxoSmithKline

Completed

Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)

Irritable Colon

United States, Spain, South Africa, Sweden, Australia, Canada, Germany, United Kingdom, France, Netherlands
Sheffield Teaching Hospitals NHS Foundation Trust

Recruiting

Traditional Dietary Advice Vs. Mediterranean Diet in IBS

Irritable Bowel Syndrome

United Kingdom
Sheffield Teaching Hospitals NHS Foundation Trust

Completed

A Study Comparing the Effectiveness and Convenience of Dietary Therapy for Irritable Bowel Syndrome (IBS)

Irritable Bowel Syndrome

United Kingdom
Bausch Health Americas, Inc.

Completed

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS) (TARGET 2)

Non-Constipation Irritable Bowel Syndrome

United States
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome With Constipation

United States
Ironwood Pharmaceuticals, Inc.
Allergan Sales, LLC

Completed

A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome Characterized by Constipation

United States
Boston Pharmaceuticals

Completed

Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

Diarrhea-predominant Irritable Bowel Syndrome

United States
Ardelyx

Completed

A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C (T3MPO-2)

Constipation Predominant Irritable Bowel Syndrome

United States
Tioga Pharmaceuticals
RTI Health Solutions

Completed

Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)

Diarrhea Predominant Irritable Bowel Syndrome

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Terminated

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation (LIN-MD-63)

Irritable Bowel Syndrome With Constipation

United States, Canada
Menarini Group

Completed

12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) (IRIS-3)

Irritable Bowel Syndrome With Diarrhea

France, Italy, Spain, United States, Russian Federation, Germany, Bulgaria, Poland, United Kingdom, Romania, Czech Republic
CinPhloro Pharma, LLC

Recruiting

Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).

Irritable Bowel Syndrome With Diarrhea

United States
Bausch Health Americas, Inc.

Completed

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C) (IBS-C)

Irritable Bowel Syndrome Characterized by Constipation

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation

Irritable Bowel Syndrome With Constipation | Chronic Idiopathic Constipation

United States
OrphoMed, Inc.
PPD

Completed

A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Irritable Bowel Syndrome With Diarrhea

United States
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome With Constipation

United States
Menarini Group

Terminated

52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) (IRIS-4)

Irritable Bowel Syndrome With Diarrhea

Germany, Sweden, United States, United Kingdom, Hungary, Poland, Latvia, Slovakia, Czech Republic
Bausch Health Americas, Inc.

Completed

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C) (CIBS)

Irritable Bowel Syndrome Characterized by Constipation

United States
Ironwood Pharmaceuticals, Inc.

Completed

Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome With Constipation

United States, Canada
AstraZeneca
Ironwood Pharmaceuticals, Inc.

Completed

A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C) (D5630C00001)

Irritable Bowel Syndrome With Constipation (IBS-C)

United States, Australia, China, New Zealand, Canada
AbbVie
Ironwood Pharmaceuticals, Inc.

Enrolling by invitation

Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

Irritable Bowel Syndrome With Constipation | Functional Constipation

United States, Canada, Israel, Netherlands
Alizyme

Terminated

Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

Constipation-Predominant Irritable Bowel Syndrome

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome With Constipation | Chronic Constipation

United States, Canada
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome Characterized by Constipation

United States, Canada
Bausch Health Americas, Inc.

Completed

Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C) (IBS-C)

Irritable Bowel Syndrome Characterized by Constipation

United States
AbbVie
Ironwood Pharmaceuticals, Inc.

Active, not recruiting

Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) (LINZESS)

Irritable Bowel Syndrome With Constipation | Functional Constipation

United States, Belgium, Bulgaria, Canada, Estonia, Israel, Italy, Netherlands, Poland, Puerto Rico, Spain, Ukraine, United Kingdom, Germany
Bausch Health Americas, Inc.

Completed

Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study (TARGET3)

Irritable Bowel Syndrome With Diarrhea

United States, United Kingdom, Germany
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome With Constipation | Chronic Constipation

United States
Ironwood Pharmaceuticals, Inc.
Allergan Sales, LLC

Completed

A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome With Diarrhea (IBS-D)

United States
Urovant Sciences GmbH

Completed

Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Arena Pharmaceuticals

Terminated

Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D) (CAPTIVATE)

Irritable Bowel Syndrome

United States
Procter and Gamble
Alimentary Health Ltd

Completed

Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Irritable Bowel Syndrome

Irritable Bowel Syndrome

United Kingdom
Neovacs

Completed

Safety and Immunogenicity of a TNFa Kinoid in Patients With Crohn's Disease

Crohn's Disease

Switzerland, South Africa
Dynogen Pharmaceuticals

Completed

8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS

Irritable Bowel Syndrome

Canada, United States
4D pharma plc

Completed

A Trial for New Treatment of Adult Participants With Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States, United Kingdom, Ireland
Lexicon Pharmaceuticals

Completed

Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States

3

Subscribe